Article

Pharmacopeia, Allergan align to research AMD compounds

Pharmacopeia and Allergan Inc. have agreed to evaluate proprietary active lead compounds-which could possibly turn into a new means for treating the wet form of age-related macular degeneration.

Allergan provided Pharmacopeia-which discovered the compounds that target angiogenesis-an upfront cash payment, the companies said in a statement. Allergan said it also might be providing preclinical and clinical payments plus milestone payments and royalties on ophthalmic drugs developed by Allergan. Pharmacopeia said it has retained the rights to other therapeutic areas.

“Partnering this program, which was initiated and advanced at Pharmacopeia, with Allergan, a recognized leader in ocular diseases, is consistent with our strategy of partnering programs outside of our therapeutic focus at earlier stages when it is advantageous to do so,” said Les Browne, PhD, Pharmacopeia president and chief executive officer.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.